{'fraction_non_alphanumeric': 0.03008595988538682, 'fraction_numerical': 0.03724928366762178, 'mean_word_length': 4.873949579831932, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Another success for hepatitis A vaccine.

Before the licensure of the first inactivated hepatitis A vaccine in 1995, hepatitis A caused a substantial disease burden in the United States. Annual cases reported to the Centers for Disease Control and Prevention (CDC) numbered 25,000 to 30,000, but a more accurate estimate approached 300,000, since infection in young children often was subclinical and mild and self-limited disease in adults was underreported.1 Infection rates were highest among children younger than 5 years of age, but only 30% of these children were symptomatic. Older children and adults had lower infection rates, but in approximately 70% of cases they were symptomatic. . . .